Form DRS - Draft Registration Statement:
SEC Accession No. 0000950123-21-000524
Filing Date
2021-01-22
Accepted
2021-01-22 16:13:05
Documents
11

Document Format Files

Seq Description Document Type Size
1 filename1.htm DRS 1356234
2 GRAPHIC g111280g04v42.jpg GRAPHIC 58189
3 GRAPHIC g111280g61a55.jpg GRAPHIC 84779
4 GRAPHIC g111280g71a90.jpg GRAPHIC 101211
5 GRAPHIC g111280g72v00.jpg GRAPHIC 102194
6 GRAPHIC g111280g80v00.jpg GRAPHIC 93723
7 GRAPHIC g111280g82v00.jpg GRAPHIC 98738
8 GRAPHIC g111280g82v01.jpg GRAPHIC 57983
9 GRAPHIC g111280g83v00.jpg GRAPHIC 64231
10 GRAPHIC g111280g85v00.jpg GRAPHIC 115628
11 GRAPHIC g111280g89n71.jpg GRAPHIC 57648
  Complete submission text file 0000950123-21-000524.txt   2474649
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
AgenTus Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: DRS | Act: 33 | File No.: 377-04074 | Film No.: 21545926
SIC: 2836 Biological Products, (No Diagnostic Substances)